Photodynamic drug therapy prevents restenosis:
This article was originally published in Clinica
Executive Summary
The first few patients treated with a new photodynamic therapy for reducing restenosis of vessels following angioplasty showed no levels of clinically significant restenosis, according to six-month angiographic follow-up. Of eight lesions (seven patients) treated with Levulan (aminolevulinic acid HC1, DUSA Pharmaceuticals), three showed no evidence of restenosis; three had 25% restenosis; and two had 40% restenosis. The results of the pilot study, from the University College Hospitals in London, UK, were reported in the October issue of the British Journal of Surgery.